4-HO-DiPT
4-HO-DiPT is a psychedelic substance of the tryptamine class structurally related to psilocin.1 First described in scientific literature by 1977 and later detailed by Alexander Shulgin in TiHKAL (1997)12, it is distinguished by its unusually rapid onset, short duration, and steep dose-response curve.1 Idiosyncratic physical effects such as muscle tremors and bodily malaise have been noted. It remains relatively uncommon with a limited history of human use and poorly understood toxicity.
Contents
Dosage & Duration
Dosage
Reported to have an especially steep dose-response curve and narrow dose range; doses below 10 mg have produced few to no effects, while doses above 20 mg have generally not been tested due to the intensity of effects.
Duration
Subjective Effects
Effects vary widely by individual, dose, and context.
Physical
Cognitive
Visual
Auditory
by Josie KinsAugust 2016.Reagent Testing
Loading reagent data
Pharmacology
Pharmacodynamics
4-HO-DiPT acts as a serotonin receptor agonist with primary activity at the 5-HT2A receptor34, where it is thought to function as a partial agonist and through which its psychedelic effects are believed to be mediated. It also activates 5-HT2B receptors5 and, with comparatively lower potency, 5-HT2C receptors, though findings on the degree of 5-HT2A versus 5-HT2C selectivity vary between studies.345 The substance may additionally act as a serotonin reuptake inhibitor45, although its potency at the serotonin transporter has been inconsistent across studies. Unlike many other tryptamines, 4-HO-DiPT does not appear to be a ligand of the rodent trace amine-associated receptor 1 (TAAR1).
Pharmacokinetics
Very little is known about the metabolism of 4-HO-DiPT in humans.6 The elimination half-life has been measured at 2.7 to 4.1 hours following subcutaneous administration of its prodrug luvesilocin (4-GO-DiPT).6
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Unsafe
AvoidThere is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
Caution
Use cautionThese combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Tolerance
Serotonergic psychedelics7
Harm Potential
Addiction & Dependence
Psychological
Extremely Low4-HO-DiPT is not regarded as habit-forming, and repeated use may reduce a person's desire to take it. Similar to most tryptamine psychedelics, it is considered self-regulating.7
Physical
Extremely LowNo physical dependence has been reported. As a tryptamine psychedelic, it does not produce physical withdrawal symptoms.7
Psychosis Risk
Delusions are listed among possible cognitive effects. As with other psychedelics, adverse psychological reactions may become more likely at higher doses, though specific psychosis risk data for this substance has not been established.
Seizure Risk
Seizure risk has not been specifically studied for this substance.
History & Culture
4-HO-DiPT was first described in the scientific literature in 1977, with its synthesis published by chemist David B. Repke.12 Two decades later, Alexander Shulgin investigated the substance's effects in humans and…
Trip Reports
Loading related reports
Preparing section content
Still loading. Refresh if this section does not appear.
Legality
By Country
References
Source Pages
Citations
- (23 June 2022). 4-HO-DiPT. Psychedelic Science Review. https://psychedelicreview.com/compound/4-ho-dipt/12345678
- (n.d.). The elimination half-life of 4-HO-DiPT in humans when given in the form of its prodrug luvesilocin (4-GO-DiPT) by subcutaneous injection has been found to range fro. https://doi.org/10.3389/fnint.2018.0005412
- (April 2021). Investigation of the Structure-Activity Relationships of Psilocybin Analogues. ACS Pharmacol Transl Sci, 4(2), 533–542. https://doi.org/10.1021/acsptsci.0c0017612
- (April 2023). Pharmacologic Activity of Substituted Tryptamines at 5-Hydroxytryptamine (5-HT)2A Receptor (5-HT2AR), 5-HT2CR, 5-HT1AR, and Serotonin Transporter. J Pharmacol Exp Ther, 385(1), 62–75. https://doi.org/10.1124/jpet.122.001454123
- (April 2023). Receptor Binding Profiles for Tryptamine Psychedelics and Effects of 4-Propionoxy-N,N-dimethyltryptamine in Mice. ACS Pharmacol Transl Sci, 6(4), 567–577. https://doi.org/10.1021/acsptsci.2c00222123
- (2025). Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous RE104: A Double-Blind, Randomized, Single Ascending Dose Placebo-Controlled Study. J Clin Psychopharmacol, 45(5), 441–453. https://doi.org/10.1097/jcp.0000000000002047123
- Matthew W Johnson, Roland R Griffiths, Peter S Hendricks, & Jack E Henningfield. (2018). The Abuse Potential of Medical Psilocybin According to the 8 Factors of the Controlled Substances Act. Neuropharmacology, 142, 143-166. https://doi.org/10.1016/j.neuropharm.2018.05.012123
- (21 July 2022). Field Trip Announces First Dosings in Phase I Clinical Study of FT-104. https://www.globenewswire.com/en/news-release/2022/07/21/2483532/0/en/Field-Trip-Announces-First-Dosings-in-Phase-I-Clinical-Study-of-FT-104.html1
- (2026-02-23). U.S. FDA Grants Reunion Neuroscience's Luvesilocin (RE104) Breakthrough Therapy Designation Status. Reunion Neuroscience. https://reunionneuro.com/2026/02/23/u-s-fda-grants-reunion-neurosciences-luvesilocin-re104-breakthrough-therapy-designation-status/1
- (June 2024). RE104: Synthesis and Activity of a Novel Serotonergic Psychedelic Prodrug of 4-Hydroxy-N,N-diisopropyltryptamine. ACS Chem Neurosci, 15(12), 2386–2395. https://doi.org/10.1021/acschemneuro.4c0005812
- (n.d.). Valtioneuvoston asetus kuluttajamarkkinoilta kielletyistä psykoaktiivisista aineista (1130/2014). Finlex / Sosiaali- ja terveysministeriö. https://www.finlex.fi/fi/laki/ajantasa/2014/201411301
- (n.d.). Anlage 1 NpSG (generic structural class definitions, including tryptamine-derived compounds). Bundesamt für Justiz / gesetze-im-internet.de. https://www.gesetze-im-internet.de/npsg/anlage_1.html1
- (2019). § 4 NpSG. https://www.gesetze-im-internet.de/npsg/__4.html12
- (2019). § 3 NpSG. https://www.gesetze-im-internet.de/npsg/__3.html12
- (n.d.). Svensk författningssamling. http://www.notisum.se/rnp/sls/sfs/20050026.pdf1
- (n.d.). Lag (1999:42) om förbud mot vissa hälsofarliga varor, 3 §. Sveriges riksdag. https://www.riksdagen.se/sv/dokument-och-lagar/dokument/svensk-forfattningssamling/lag-199942-om-forbud-mot-vissa-halsofarliga_sfs-1999-42/1
- (1971). Schedule 2: Part I: Class A Drugs. http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I1
- (2022). Schedules of Controlled Substances: Placement of 4-hydroxy-N,N-diisopropyltryptamine (4-OH-DiPT) in Schedule I; Withdrawal of Proposed Rule and Notice of Hearing. Drug Enforcement Administration. https://www.govinfo.gov/content/pkg/FR-2022-07-27/html/2022-16102.htm1
- (n.d.). Statutes & Constitution :View Statutes : Online Sunshine. leg.state.fl.us. http://leg.state.fl.us/statutes/index.cfm?App_mode=Display_Statute&URL=0800-0899/0893/0893.html1
Further Reading
Chadeayne et al. (2025). 4-Hydroxy-N,N-diisopropyltryptammonium hydrofumarate crystal structure
Drugs-Forum: 4-HO-DiPT Trip Reports- Glatfelter et al. (2023). Binding and functional activity of psilocin analogs at serotonin receptors
- Kelly et al. (2024). Psychedelic tryptamine pharmacology and therapeutic potential
- Repke et al. (1977). Psilocin analogs synthesis
- Repke, D. B. et al. (1977). Psilocin analogs synthesis
- Reviewed & approved
Reviewed, edited, and approved by subject-matter expert Lyrea.
Automated synthesisInformation aggregated and synthesized using an autonomous workflow built by Josie Kins.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the 4-HO-DiPT article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
